In-Stent Coronary Artery Restenosis
10
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.0%
1 terminated out of 10 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
The PICCOLETO XI A-PREP Study
SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI
Resveratrol Excipient Paclitaxel Coated Balloon for Coronary Treatment
REWARDS- In-stent Restenosis
Prognostic Assessment of Different Pattern of Bifurcation Restenosis
A Randomized Clinical Evaluation of the BioFreedom™ Stent
Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST)
Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation
Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis
In-stent Restenosis in Patients With Patent Previous Bare Metal Stent